
Loading, please wait...

Loading, please wait...

Ischemic stroke remains a principal cause of death and long-term physical impairment globally. After acute vascular occlusion, sudden nutrient deprivation causes substantial cellular injury. Subsequently, an intense secondary inflammatory cascade worsens the tissue damage across vulnerable ischemic brain tissue. In this pathophysiological cascade, resident microglia respond swiftly to metabolic changes. These immune cells orchestrate early neuroinflammatory defense, but they can exacerbate cellular destruction when chronically activated. Consequently, modulating microglial polarization from a cytotoxic M1 phenotype toward a protective M2 phenotype represents an effective neuroprotective approach. Although conventional reperfusion modalities re-establish arterial perfusion, they cannot suppress persistent microglial activation. Therefore, targeted immunomodulatory interventions are necessary to halt progressive neuronal necrosis. Chuanxiong essential oil, derived from Ligusticum chuanxiong, displays remarkable antioxidant, anti-thrombotic, and anti-inflammatory qualities. However, severe pharmacological limitations restrict its clinical utility, including low water solubility, high volatility, and inadequate blood-brain barrier penetrability. To address these pharmacokinetic challenges, scientists are designing biomimetic nanocarriers. Combining synthetic vesicles with native cell membranes provides an elegant delivery system that shields fragile compounds while enhancing biological uptake. Accordingly, this breakthrough formulation aims to reprogram neuroinflammatory cascades and support neural repair.
To overcome systemic delivery hurdles, investigators engineered an innovative biomimetic nanoplatform labeled CXEO-LP@M2M. This sophisticated carrier embeds Chuanxiong essential oil into lipid nanoparticles and cloaks them with extracted M2-like microglial membranes. Physical characterization showed a monodisperse nanoparticle formulation with an average hydrodynamic diameter of 150.6 ± 2.80 nanometers. Furthermore, the hybrid vesicles exhibited a net surface zeta potential of -12 ± 2.52 millivolts, conferring suitable colloidal stability. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blot assays confirmed that the outer shell successfully retained functional M2-like microglial membrane proteins. Moreover, dual-dye fluorescence colocalization verified intact membrane integration across the lipid core without destabilizing structural vesicle architecture. The encapsulation efficiency reached an impressive 80.19 percent, alongside a reliable drug loading rate of 2.22 percent. Crucially, CXEO-LP@M2M exhibited stable colloidal suspension properties throughout cold storage at 4 degrees Celsius. In vitro dissolution profiles revealed a sustained release pattern, allowing slower and more controlled release of volatile components than free oil. Hence, this hybridized carrier preserves volatile phytochemicals while avoiding rapid enzymatic degradation in systemic circulation. As a result, the nanoplatform successfully delivers intact therapeutic agents directly toward inflamed brain targets.
Investigators examined intracellular delivery and biological responses using in vitro BV2 microglial cell models. Cellular internalization assays demonstrated that BV2 cells absorbed CXEO-LP@M2M at significantly higher rates than unmodified liposomes. This enhanced intracellular uptake occurs via homotypic cell recognition, because preserved membrane proteins bind specific receptors on target cells. When exposed to inflammatory stimuli, resting microglia transition into the aggressive M1 phenotype, producing destructive inflammatory cascades. Fortunately, treatment with CXEO-LP@M2M markedly diminished these cytotoxic cellular reactions. The formulation significantly decreased the secretion of major pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6. In addition, the biomimetic liposomes actively upregulated protective markers, driving microglial polarization toward the neuroprotective M2 phenotype. This phenotypic switch suppressed downstream neurotoxic signaling cascades and preserved mitochondrial functionality in neighboring cells. These compelling cellular findings prove that the membrane-coated platform enhances intracellular bioavailability while exerting powerful direct immunomodulatory actions. Consequently, CXEO-LP@M2M mitigates neuroinflammation at the cellular level by converting pathological microglia into reparative phenotypes. Thus, the system offers dual benefits through targeted drug delivery and phenotypic modulation.
To evaluate in vivo therapeutic potential, researchers applied a bilateral common carotid artery occlusion and reperfusion model in mice. Administration of CXEO-LP@M2M led to substantial improvements in sensorimotor performance and neurological deficit scores. Furthermore, volumetric brain assessments revealed significant reductions in cerebral edema and overall infarct size compared to controls. Histological examinations confirmed preserved neuronal morphology within the ischemic cortex, showing reduced cellular pyknosis and apoptotic fragmentation. Moreover, the biomimetic formulation attenuated dangerous oxidative stress markers, lowering malondialdehyde concentrations and restoring endogenous superoxide dismutase activity. Immunofluorescence analyses verified marked phenotypic transformation in the ischemic penumbra, characterized by reduced M1 markers and increased M2-specific markers. Importantly, the researchers administered the formulation via the intranasal route, successfully delivering nanocarriers across the blood-brain barrier. Intranasal delivery exploits olfactory and trigeminal neuronal pathways, transporting therapeutic agents directly into brain parenchyma while bypassing peripheral vascular clearance. Consequently, the nanomedicine achieved superior intracranial concentrations without inducing systemic toxicities. Therefore, in vivo results validate CXEO-LP@M2M as a highly potent early neuroprotective therapy for acute ischemic stroke.
Ischemic stroke remains a formidable therapeutic challenge, as acute management options remain largely restricted to mechanical and chemical revascularization. While reperfusion therapies preserve ischemic penumbra, secondary reperfusion injury continually drives neurovascular breakdown and long-term disability. Therefore, incorporating targeted neuroprotective interventions into early stroke care protocols could significantly enhance functional clinical recovery. The biomimetic CXEO-LP@M2M platform highlights the immense clinical promise of combining traditional phytochemicals with modern nanomedicine. Furthermore, utilizing biomimetic cell membrane cloaking strategies resolves critical pharmacological hurdles related to targeted brain delivery and immune evasion. The non-invasive intranasal route also allows rapid drug administration in pre-hospital or emergency department settings. However, clinical translation demands thorough resolution of several technical and regulatory hurdles. Clinicians and formulation scientists must establish scalable, reproducible isolation protocols for microglial membranes that comply with clinical manufacturing requirements. Additionally, comprehensive toxicological evaluations and pharmacokinetic testing in larger animal models must precede human clinical trials. Nonetheless, these pre-clinical breakthroughs indicate that active microglial modulation offers a revolutionary therapeutic paradigm for managing post-stroke neuroinflammation.
Microglia display distinct functional phenotypes following acute cerebral ischemia. During early injury, resting microglia transition into a cytotoxic M1 phenotype, releasing tumor necrosis factor-alpha, interleukin-1 beta, and reactive oxygen species that accelerate neuronal apoptosis and disrupt the blood-brain barrier. Conversely, reparative M2 microglia release anti-inflammatory cytokines and clear cellular debris. Therefore, redirecting microglial polarization toward the M2 phenotype protects viable penumbral brain tissue, reduces secondary edema, and improves neurological recovery.
Coating liposomes with M2-like microglial membranes provides a sophisticated biomimetic camouflage that improves therapeutic targeting. Endogenous membrane proteins on the hybrid vesicles promote homologous adhesion and recognition, allowing recipient microglial cells to internalize the nanocarrier via active receptor-mediated endocytosis. Furthermore, this natural membrane prevents premature phagocytic elimination by peripheral immune cells. When administered intranasally, the functionalized nanoparticles successfully bypass the blood-brain barrier, maximizing active compound concentration directly within ischemic brain regions.
Chuanxiong essential oil contains potent therapeutic components, including volatile phthalides such as ligustilide and butylidenephthalide, which possess robust neuroprotective properties. These phytochemicals alleviate cerebral ischemia by suppressing inflammatory signaling cascades, scavenging damaging free radicals, and mitigating mitochondrial dysfunction. Furthermore, the essential oil enhances microvascular perfusion and downregulates pro-inflammatory cytokine expression. Incorporating this natural formulation into biomimetic liposomes overcomes its poor stability and solubility, providing concentrated therapeutic delivery to inflamed neural tissues.
Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Always seek the advice of a healthcare provider with any questions you may have regarding a medical condition. Clinical decisions should not be based solely on this information. The views expressed are those of the authors and do not necessarily reflect the official policy or position of any medical institution. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Novel biomimetic liposomes coated with M2-like microglial membranes and loaded with Chuanxiong essential oil successfully promote microglial polarization from M1 to M2, significantly dampening neuroinflammation and reducing cerebral edema in preclinical ischemic stroke models.
Today

A recent experimental study demonstrates that pre-challenge montelukast administration attenuates food-allergic responses and reduces colonic eosinophilic inflammation, providing valuable insights into leukotriene-mediated pathways in gastrointestinal allergic disorders.
Today

A single-center study evaluates fetal shunt placement in twin gestations with severe lung lesions or bladder outlet obstruction. Findings demonstrate an 85.7% 30-day survival rate in treated fetuses and 100% survival among unaffected co-twins, showing that experienced centers can perform the procedure safely.
Today

A new scoping review and expert consensus establish a concise 16-measure performance bundle for hospital cardiology services. Covering clinical processes, outcomes, patient-reported experiences, and structural factors, this framework advances value-based cardiovascular care under universal health coverage.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Today

New research links de novo truncating variants in ZNF462 to congenital hypogonadotropic hypogonadism and Kallmann syndrome in Weiss-Kruszka syndrome. These findings reveal critical neurodevelopmental and epigenetic mechanisms governing GnRH neuron deficiency, offering new diagnostic clarity for clinicians.
Today